Therachon
Webb6 nov. 2024 · Key operating players in global achondroplasia treatment market are Ascendis Pharma A/S, BridgeBio Pharma, Inc., QED Therapeutics, BioMarin Pharmaceutical Inc., Pfizer Inc., Therachon Holding AG, and RIBOMIC Inc. Market Taxonomy: On the basis of drug class, the global achondroplasia treatment market is segmented into: Lipase … Webb9 maj 2024 · May 9, 2024 - Updated on June 24, 2024. 2 minutes. Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development …
Therachon
Did you know?
Webb17 aug. 2024 · Swiss-based biotech company, Therachon, which focuses on developing rare genetic disease treatments, says it has closed a $60 million round of funding as the company moves closer to a drug trial. The funding will be used to develop the company’s treatment for achondroplasia, the most common form of short limbed dwarfism, and … WebbFresh off a $60 million raise, the Novo Holdings-backed startup Therachon announced plans to buy GLyPharma Therapeutic and make the leap to becoming a multi-asset rare disease company.
Webb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with … Webb9 aug. 2024 · Therachon has raised a total of $100M in funding over 3 rounds. Their latest funding was raised on Aug 9, 2024 from a Series B round. Therachon is funded by 9 …
Webb1 juli 2024 · Early clinical development program for achondroplasia augments Pfizer’s Rare Disease portfolio ... April 13, 2024 Webb8 maj 2024 · May 8, 2024. Pfizer has agreed to acquire Therachon Holdings for up to $810 million, the companies said today, in a deal intended to expand the buyer’s rare disease portfolio with a pipeline to ...
WebbHQ / GMP : #712-715, Sagimakgol-ro 137, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea 13202 R&D Center : #1004-1005, Galmachiro 302, Jungwon-gu, Seongnam-si, Gyeonggi …
Webb8 jan. 2024 · The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare … birch tree yogaWebb30 jan. 2024 · BASEL, Switzerland, Jan. 30, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative ... dallas public library forest green branchWebb25 mars 2024 · Therachon is committed to making a difference in the lives of patients living with serious rare disorders. For more information, please visit … birch trim boardshttp://therachon.com/research/ dallas public library central hoursWebbTherAchon is a biotech company specializing in research and development. It is engaged in the development of a recombinant protein therapy for achondroplasia, the most … birch truffle hardwood flooringWebbTherachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions … birch tree with red leavesWebb29 nov. 2024 · Apraglutide, with once-weekly administration, is a potential best-in-class therapeutic for the treatment of short bowel syndrome. BASEL, Switzerland, Nov. 29, 2024 /PRNewswire/ -- Therachon AG ... dallas public library catalog city of dallas